Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow A corrigendum has been published
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Colombo, T.
Right arrow Articles by D'Incalci, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colombo, T.
Right arrow Articles by D'Incalci, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:801-805, 1996
© 1996 European Society for Medical Oncology

other

Paclitaxel induces significant changes in epidoxorubicin distribution in mice

T. Colombo1, O. Gonzalez Paz1, M. Zucchetti1, M. Maneo1, C. Sessa2, A. Goldhirsch2 and M. D'Incalci1,

1Laboratory of Cancer Pharmacology, Department of Oncology, Mario Negri Institute for Pharmacological Research Milan, Italy
2Division of Oncology, Ospedale San Giovanni Bellinzona, Switzerland

Correspondence to: Dr. Maurizio D'Incalci Istituto di Ricerche Farmacologiche Mario Negri via Eritrea 62 I-20157 Milan Italy

BACKGROUND:: Inhibition of Pgp can affect the distribution and the pharmacokinetics of anthracyclines, causing marked changes in their toxicity. Since both paclitaxel and cremophor are substrates of Pgp, it was hypothesized that they could modify the pharmacokinetics of anthracyclines in a similar fashion.

PURPOSE OF THE STUDY:: To evaluate whether pretreatment of mice with cremophor or paclitaxel dissolved in cremophor could induce changes in the distribution of epidoxorubicin (EpiDx).

MATERIALS AND METHODS:: Male CDF1 mice were treated with ethanol or cremophor or paclitaxel and 30 min later with EpiDx (15 mg/kg i.v.). EpiDx serum and tissue levels were determined at several time points after EpiDx treatment by high pressure liquid chromotagraphy (HPLC) assay coupled with fluorimetric detection.

RESULTS:: Pretreatment with paclitaxel dissolved in cremophor induced a highly significant increase in EpiDx levels in all tissues examined including heart. At 8 h heart levels in mice treated with EpiDx alone, EpiDx and cremophor and EpiDx and paclitaxel were 8.3 µg/g, 10.9 µg/g and 16.7 µg/g (P<0.01), respectively. Cremophor alone induced a similar increase in spleen EpiDx levels but had only a moderate effect on heart and lung EpiDx levels. Levels of doxorubicin (Dx) aglycone in kidney and liver of mice treated with paclitaxel and EpiDx were higher than those in mice treated with EpiDx alone.

CONCLUSIONS:: A pharmacokinetic interaction between paclitaxel and EpiDx was clearly demonstrated in mice. The much higher tissue levels of EpiDx after paclitaxel pretreatment may be the reason for the increased toxicity of EpiDx when administered soon after paclitaxel.

epidoxorubicin, interactions, paclitaxel, pharmacokinetics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
L. Couture, J. A. Nash, and J. Turgeon
The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart.
Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Esposito, M. Venturini, M.O. Vannozzi, G. Tolino, G. Lunardi, O. Garrone, C. Angiolini, M. Viale, M. Bergaglio, L. Del Mastro, et al.
Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients
J. Clin. Oncol., April 1, 1999; 17(4): 1132 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sparano, J. Speyer, W. J. Gradishar, L. Liebes, R. Sridhara, S. Mendoza, D. Fry, and M. J. Egorin
Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer
J. Clin. Oncol., March 1, 1999; 17(3): 880 - 880.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.